July 7, 2025
Montreal, July 7,2025 – CellCarta, leading provider of specialized clinical laboratory services, is pleased to announce the appointment of Elliott Miller as Chief Financial Officer.
Elliott brings a unique blend of finance experience and progressive leadership roles spanning global corporate operations and clinical research. He began his career at General Electric, where he gained valuable expertise in operational excellence and strategic growth within a complex, global environment. Most recently, Elliott served as Senior Vice President of Finance at Thermo Fisher Scientific, where he led the Clinical Development Services Division (PPD), an industry-leading contract research organization spanning Phase I-IV clinical trials.
In his new role at CellCarta, Elliott will oversee all aspects of the company’s financial strategy, supporting our continued growth and commitment to operational and scientific excellence. His deep industry expertise and customer-centric approach make him a valuable addition to our leadership team.
“The appointment of Elliott Miller as CFO marks an exciting new chapter for CellCarta,” said Dusty Tenney, Chief Executive Officer. “His strategic mindset, operational rigor, and industry knowledge will be instrumental in strengthening CellCarta’s financial foundation as we continue to deliver exceptional science, innovation, and value to our customers throughout the drug development lifecycle. We are confident Elliott will help drive long-term value for our shareholders, customers and employees as we continue to propel precision medicine forward.”
About CellCarta
CellCarta is a leading global contract research organization (CRO) serving the biopharmaceutical industry. With CAP accreditations and CLIA certifications for advanced assays and fully integrated quality management systems across Canada, the United States, Belgium, Australia and China, the company delivers comprehensive biomarker testing services and tailored solutions to the world’s leading pharmaceutical companies. CellCarta’s integrated platforms in immunology, histopathology, proteomics and genomics platforms, together with its sample management and logistics systems, enable the company to provide clients comprehensive, full-cycle support throughout the drug discovery process, from early-stage research to late-stage clinical trials.
Posters
June 23, 2025
More infoPosters
June 23, 2025
More infoCellTalk Blog
June 10, 2025
More infoCellTalk Blog
June 4, 2025
More info